"Tirzepatide, the active ingredient in Eli Lilly’s Zepbound and diabetes injection Mounjaro, likely won’t be eligible for those negotiations until the end of the decade."
glp1forum.com uses cookies and other similar functionality to help us personalize content, tailor your experience and to keep you logged in if you are a registered member.
By continuing to use this site, you are consenting to our use of cookies.